Abstract
Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control. We investigated the effect of cyclin D1 (CCND1) rs9344 G>A in stage II/III colon cancer patients and validated the findings in an independent study cohort. For evaluation and validation set, a total of 264 and 234 patients were included. Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16–5.29; P=0.019). There was no significant association between CCND1 rs9344 G>A and TTR in patients with curative surgery alone. In the validation set, the A allele of CCND1 rs9344 G>A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05–3.58; P=0.035). CCND1 rs9344 G>A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
Boyle P, Ferlay J . Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481–488.
Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15: 390–404.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. Lancet 2010; 375: 1030–1047.
Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797–1806.
Winder T, Lenz HJ . Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 2010; 36: 550–556.
Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912–2919.
Sinicrope FA, Sargent DJ . Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369–373.
Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G . Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010; 28: 4029–4037.
Reed SI . The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol 1992; 8: 529–561.
Diehl JA . Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226–231.
Sellers WR, Kaelin Jr WG . Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 3301–3312.
Pirkmaier A, Yuen K, Hendley J, O'Connell MJ, Germain D . Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide. Clin Cancer Res 2003; 9: 1877–1884.
Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003; 21: 2085–2093.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J . Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005–1011.
Pagano M, Theodoras AM, Tam SW, Draetta GF . Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994; 8: 1627–1639.
Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 2010; 119: 701–705.
Rogers S, Wells R, Rechsteiner M . Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234: 364–368.
Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A . Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975–978.
Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2009; 116: 571–575.
Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 2001; 159: 1917–1924.
Arber N, Gammon MD, Hibshoosh H, Britton JA, Zhang Y, Schonberg JB et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 1999; 30: 1087–1092.
Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S . Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer 1998; 77: 92–97.
Maeda K, Chung Y, Kang S, Ogawa M, Onoda N, Nishiguchi Y et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998; 55: 145–151.
McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 2000; 88: 77–81.
Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70: 8802–8811.
Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 51: 303–311.
Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010; 30: 4209–4217.
Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16: 475–483.
Acknowledgements
This work was supported by the START research grant of the Medical University of Graz and the Daniel Butler Memorial Fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Absenger, G., Benhaim, L., Szkandera, J. et al. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. Pharmacogenomics J 14, 130–134 (2014). https://doi.org/10.1038/tpj.2013.15
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2013.15
Keywords
This article is cited by
-
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
The Pharmacogenomics Journal (2020)
-
SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with “time to event” outcomes
BMC Bioinformatics (2016)
-
Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling
Nature Methods (2016)